Novartis AG
Dosing schedule for a combination of Ceritinib and an anti-PD-1 antibody molecule

Abstract:

The present disclosure relates to the field of pharmacy, particularly to ceritinib and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising ceritinib, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.